Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects
NCT03131024 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58
Last updated 2024-09-19
Summary
Doxorubicin and epirubicin are part of the class of chemotherapy agents called anthracyclines that are commonly used to treat breast cancer. Although these treatments work well against the tumor, they are known to cause damage to the heart muscle, resulting in diminished heart function that can be permanent, and may also damage the blood vessels and skeletal muscles. The purpose of this study is to determine whether short-term application of these interventions with specific timing relative to the receipt of each treatment can prevent the negative effects of anthracycline treatment on the heart, aorta (largest artery leaving the heart), and skeletal muscle, and reduce treatment symptoms. Fifty-six early stage breast cancer patients who will receive anthracycline treatment will be randomly assigned to 1 of 3 groups who will: 1) perform a single 30-minute aerobic exercise session 24 hours prior to each treatment; 2) eat a diet consisting of 50% less calories for 48 hours prior to each treatment; or 3) receive usual cancer care. Magnetic resonance imaging (MRI) will be used to precisely measure the function of the heart, aorta, and the lower leg skeletal muscle at rest, and again during exercise to allow detection of more subtle signs of damage. We will also measure exercise capacity (i.e. aerobic fitness), microscopic damage to the heart muscle cells, a marker released into the blood in response to anthracycline-related heart damage, tumor size in patients receiving chemotherapy before surgery, quality of life and fatigue. These measures will be performed before treatment, at the end of treatment and 1 year later.
Conditions
- Breast Cancer Female
Interventions
- DIETARY_SUPPLEMENT
-
50% caloric restriction
Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
- OTHER
-
Aerobic exercise
The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
Sponsors & Collaborators
-
Susan G. Komen Breast Cancer Foundation
collaborator OTHER -
University of Alberta
lead OTHER
Principal Investigators
-
Amy A Kirkham, PhD · University of Alberta
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-15
- Primary Completion
- 2021-05-05
- Completion
- 2021-05-05
Countries
- Canada
Study Locations
More Related Trials
-
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
NCT06881940 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
NCT05716893 ·Status: RECRUITING ·Phase: PHASE2
-
Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)
NCT03748550 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
NCT06387901 ·Status: RECRUITING
-
Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT03280836 ·Status: COMPLETED ·Phase: NA
-
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
NCT01708798 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
NCT05732051 ·Status: RECRUITING ·Phase: PHASE2
-
Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy
NCT06190600 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
NCT00424203 ·Status: COMPLETED ·Phase: PHASE2
-
STOP Heart Disease in Breast Cancer Survivors Trial
NCT02674204 ·Status: TERMINATED ·Phase: PHASE2
-
EXercise Influence on Taxane Side Effects (EXIT) Study
NCT02473861 ·Status: COMPLETED ·Phase: NA
-
Docetaxel in Treating Older Women With Metastatic Breast Cancer
NCT00104624 ·Status: TERMINATED ·Phase: PHASE2
-
MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study
NCT01246856 ·Status: UNKNOWN
-
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
NCT07070765 ·Status: RECRUITING ·Phase: NA
-
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
NCT00004125 ·Status: COMPLETED ·Phase: PHASE3
-
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
NCT00895414 ·Status: COMPLETED ·Phase: NA
-
Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer
NCT00074139 ·Status: WITHDRAWN ·Phase: PHASE1
-
The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function
NCT03062878 ·Status: COMPLETED
-
Survival TRaining for ENhancing Total Health (STRENGTH)
NCT00068458 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
NCT00872625 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses
NCT04568161 ·Status: COMPLETED ·Phase: NA
-
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
NCT01301040 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
NCT00527449 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
NCT03705429 ·Status: COMPLETED ·Phase: PHASE3
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970 ·Status: COMPLETED ·Phase: PHASE3